New pill cuts heart attack deaths
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The drugs giant AstraZeneca has announced that its trials of a new blood thinning pill produced a 16 per cent drop in heart attack and stoke deaths among patients.
The group said the drug, Brilinta, worked better than Plavix, which is the world's second biggest selling drug, without increasing the risk of bleeding, a common side-effect of medication that reduces heart attacks by preventing blood clots.
AstraZeneca now plans to apply for regulatory approval for Brilinta in the US and Europe during the final quarter of the year, with a view to making it available as soon as possible, possibly by the end of 2010. The trial involved 18,624 patients, half were given Brilinta after suffering a heart attack or stroke, and half were given Plavix.
The study found there were 14 fewer deaths per 1,000 patients among those who were given Brilinta. The positive results of the trial should help the drug win a slice of the Plavix market, which is worth around £5.5bn a year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments